Related Experiment Videos
[Phase I study with LH-RH agonist, ICI 118630]
Hinyokika Kiyo. Acta Urologica Japonica
|March 1, 1986
Summary
This study confirmed the safety of Zoladex (a gonadotropin-releasing hormone agonist) in healthy males. Endocrinal effects were observed, validating its function as an LH-RH agonist.
Area of Science:
- Endocrinology
- Pharmacology
Context:
- Investigating novel therapeutic agents for hormonal regulation.
- Assessing the physiological impact of synthetic hormone analogs.
Purpose:
- To evaluate the safety and endocrinal effects of a single 250 microgram dose of Zoladex (ICI 118630), a gonadotropin-releasing hormone agonist.
- To confirm the drug's classification as an LH-RH agonist through observed hormonal changes.
Summary:
- Four healthy male volunteers received a subcutaneous injection of 250 micrograms of Zoladex.
- No adverse clinical effects or vital sign abnormalities were noted, confirming drug safety.
- Blood samples revealed expected changes in Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and testosterone levels, consistent with LH-RH agonist activity.
Impact:
- Establishes the safety profile of Zoladex in healthy males.
- Provides evidence for the endocrinal mechanism of action of this LH-RH agonist.
- Supports the potential use of Zoladex in clinical applications requiring hormonal modulation.